Immetas Therapeutics

In a lab off Eagle Rock Avenue in East Hanover, New Jersey, a small team is studying a fire that almost no one can see. It does not flare. It smolders - low, chronic, and quiet - and it has been linked to more than half of all deaths on Earth. The team at Immetas Therapeutics has a name for it: inflammaging. And they are trying to build the drugs that turn it down.

This is not a longevity startup selling supplements and optimism. Immetas is a discovery-stage biotech with a narrow, stubborn idea: that cancer, autoimmune disease, and the simple act of getting older are not separate problems at all. They are branches of the same tree, and the trunk is inflammation.

The slow burn nobody was treating

Medicine is very good at emergencies. A broken bone, an infection, a tumor you can point to on a scan - these get protocols, drugs, and entire specialties. What medicine has been worse at is the slow stuff: the years-long, low-grade inflammation that creeps through the body as it ages and quietly sets the stage for disease.

The science here has been mounting for a decade. Chronic, sterile inflammation - inflammation without an infection to justify it - shows up in cancer, heart disease, neurodegeneration, and autoimmune conditions alike. It is a common denominator hiding in plain sight. The trouble is that "treat inflammation" is easy to say and very hard to do without switching off the immune system you actually need.

Immetas decided the answer was not a sledgehammer. It was a scalpel - aimed at the innate immune system, the body's ancient first line of defense, and specifically at the inflammasomes, the molecular sensors that decide when inflammation switches on. Tune those, the bet goes, and you can quiet the harmful signal without dismantling the rest.

A drug hunter and an aging scientist

Immetas was founded in 2018 by two people who came at the same problem from opposite ends. J. Gene Wang, MD, PhD, is the operator - a drug-development veteran who spent roughly two decades inside Merck, Abbott, GSK, and Novartis. He had a hand in medicines most people have heard of, including Humira and Gardasil. He knows how a molecule becomes a product, and how often it does not.

His co-founder, David Sinclair, PhD, is the theorist - a professor of genetics at Harvard Medical School and one of the most recognizable names in the study of aging. TIME put him on its list of the 50 most influential people in healthcare. Where Wang knows the pipeline, Sinclair knows the biology of why bodies break down over time.

It is a slightly ironic pairing for a field that loves to promise the moon: an aging researcher and a man who has watched dozens of promising drugs die in trials, teaming up to be careful. Their stated approach is almost contrarian in biotech - clinical evidence first, drug discovery second. Start with what real disease in real patients tells you, then go find the molecule. Most companies do it the other way around.

What Immetas is actually building

The lead program is a series of bispecific antibodies - engineered proteins that grab two targets at once. The goal is to regulate inflammation inside the tumor microenvironment, the hostile little ecosystem a cancer builds around itself. That ecosystem is one reason checkpoint inhibitors, the celebrated immunotherapies of the last decade, stop working for so many patients. Immetas wants to break that resistance from the inflammation side.

Notice the symmetry. In cancer, the body's inflammation is being hijacked to help a tumor hide. In autoimmune disease, that same inflammation is turned against healthy tissue. Immetas is trying to work both ends of one dial - turning it down where it harms, in a way precise enough not to leave the patient defenseless.

Small money, concentrated conviction

Immetas is not a story of a giant raise. It is the opposite - a lean company that one investor backed entirely. The chart below is less about scale than about signal: where the dollars and the partners actually landed.

The 2023 GC Biopharma deal is the other tell. A larger pharmaceutical company does not hand over its mRNA and lipid-nanoparticle delivery platforms to a tiny biotech unless it believes that biotech knows something useful about which targets to hit. Immetas brings the biology - the targets, the payload molecules, the disease strategy. GC brings the delivery vehicle. That division of labor is the clearest outside vote of confidence the company has.

One root, many diseases

The reason any of this matters is bigger than a single drug. If the inflammaging thesis is right, then treating the inflammation at the root could touch a long list of conditions that today are managed one symptom at a time. That is an enormous "if." Immetas is honest enough, in its careful framing, not to pretend the if is settled.

What the company offers instead is a discipline: start with human disease, interrogate the mechanism deeply, and only then build the molecule. It is unglamorous. It is slow. And in a field littered with the wreckage of beautiful ideas that never survived contact with patients, slow and disciplined is not the worst place to plant a flag.

Back to the fire nobody can see

Return to that lab off Eagle Rock Avenue. The fire is still smoldering - it always will be; inflammation is a feature of being alive, not a bug to be deleted. The question Immetas is chasing is not how to put it out, but how to keep it from spreading where it does harm.

If they are right, the payoff is not a single blockbuster. It is a different way of thinking about why we get sick as we get older - and a set of tools precise enough to act on it. If they are wrong, they will have failed carefully, with good data, which in drug development is its own kind of contribution.

For now, a small team in New Jersey keeps watching the slow burn, looking for the exact moment it turns destructive - and the exact molecule that can talk it back down. The fire is the same one that has been with us all along. What is new is that someone is finally trying to read it.